RXST — RxSight, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1111485 ·
Last close
$4.83
Market Cap
$202.52M
52W High
$13.22
52W Low
$4.11
ADV30
879,225
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 24,586,000 | 18,099,000 | -18,518,000 | -16,224,000 | 340,418,000 | 66,717,000 | 85,507,000 |
| Jun 2026 | 33,741,000 | 25,886,000 | -13,770,000 | -12,097,000 | 352,700,000 | 13,352,000 | 89,360,000 |
| Mar 2026 | 30,893,000 | 23,498,000 | -17,829,000 | -15,884,000 | 303,993,000 | 17,573,000 | 36,698,000 |
| Dec 2025 | 32,608,000 | 25,263,000 | -11,337,000 | -9,152,000 | 311,814,000 | 19,949,000 | 36,131,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$23,671,000
Investing CF
$11,832,000
Financing CF
$1,584,000
CapEx
$-5,026,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.28
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-705,244,000
Inventory
$39,593,000
Receivables
$16,998,000
ST Investments
$187,966,000
EBIT TTM
$-53,216,000
Pretax Income TTM
$-53,230,000
Interest Exp TTM
$14,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$121,828,000
EBITDA
$-57,842,000
Free Cash Flow
$39,379,876
Enterprise Value
$-54,004,332
Total Cash
$254,683,008
Total Debt
$10,320,000
Shares Out
41,929,222
Trailing EPS
$-1.29
Book Value
$6.08
ROE
-20.1%
ROA
-11.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 134,479,000 | -48,191,000 | -38,944,000 | 311,814,000 | 36,131,000 | 275,683,000 | -15,511,000 |
| Dec 2024 | 139,927,000 | -36,858,000 | -27,455,000 | 318,563,000 | 37,325,000 | 281,238,000 | -16,946,000 |
| Dec 2023 | 89,077,000 | -50,085,000 | -48,608,000 | 182,550,000 | 22,188,000 | 160,362,000 | -41,593,000 |
| Dec 2022 | 49,005,000 | -63,318,000 | -66,756,000 | 150,164,000 | 60,262,000 | 89,902,000 | -58,850,000 |
TTM Snapshot
Revenues TTM
$127,581,000
NetIncome TTM
$-46,949,000
OpCashFlow TTM
—
Assets (Latest)
$352,700,000
Forward EPS
$-0.68
Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $5.01 · call volume: 8 · put volume: 49
Expected Move to 2027-03-19:
±$1.98
(39.42%) —
implied range
$3.04 –
$6.99
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| UURAF | Ucore Rare Metals Inc. | $202.25M | $1.33 | — |
| KF | KOREA FUND INC | $202.93M | $48.80 | — |
| TDRRF | Tudor Gold Corp. | $202.03M | $0.49 | — |
| QSI | Quantum-Si Inc | $201.80M | $1.01 | — |
| LIEN | Chicago Atlantic BDC, Inc. | $201.73M | $8.84 | — |
News headlines (Yahoo Finance, 1h cache)
RxSight (RXST) Q3 2026 Earnings Call Transcript
2026-11-04 17:05 · Yahoo
RxSight, Inc. Q3 2026 Earnings Call Summary
2026-11-04 13:30 · Yahoo
What RxSight (RXST) Said on Its Q3 Earnings Call
2026-11-04 03:14 · Yahoo
RxSight, Inc. (RXST) Reports Q3 Loss, Lags Revenue Estimates
2026-11-03 21:50 · Yahoo
RxSight, Inc. Reports Third Quarter 2026 Results
2026-11-03 21:05 · Yahoo
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
2026-10-24 00:00 · Yahoo
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
2026-10-20 20:05 · Yahoo
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
2026-10-19 13:00 · Yahoo
RxSight's Utilization-Growth Upside Faces Structural, Competitive Headwinds, BofA Says
2026-09-23 14:42 · Yahoo
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
2026-08-26 20:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.